MML Investors Services LLC Purchases 3,000 Shares of Omeros Co. (NASDAQ:OMER)

MML Investors Services LLC lifted its position in shares of Omeros Co. (NASDAQ:OMER) by 19.2% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 18,600 shares of the biopharmaceutical company’s stock after buying an additional 3,000 shares during the quarter. MML Investors Services LLC’s holdings in Omeros were worth $74,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. HighTower Advisors LLC increased its holdings in Omeros by 7.2% during the third quarter. HighTower Advisors LLC now owns 59,339 shares of the biopharmaceutical company’s stock valued at $235,000 after buying an additional 4,000 shares during the period. Wellington Management Group LLP bought a new stake in Omeros during the 3rd quarter valued at $305,000. BNP Paribas Financial Markets increased its holdings in shares of Omeros by 130.6% in the 3rd quarter. BNP Paribas Financial Markets now owns 12,388 shares of the biopharmaceutical company’s stock valued at $49,000 after acquiring an additional 7,016 shares during the period. Bank of New York Mellon Corp raised its position in shares of Omeros by 16.6% in the 2nd quarter. Bank of New York Mellon Corp now owns 218,580 shares of the biopharmaceutical company’s stock worth $887,000 after acquiring an additional 31,081 shares in the last quarter. Finally, AQR Capital Management LLC bought a new position in shares of Omeros in the 2nd quarter worth $105,000. Hedge funds and other institutional investors own 48.79% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on the company. RODMAN&RENSHAW upgraded Omeros to a “strong-buy” rating in a research note on Thursday, November 14th. Cantor Fitzgerald restated a “neutral” rating on shares of Omeros in a report on Thursday, November 14th. StockNews.com upgraded shares of Omeros from a “sell” rating to a “hold” rating in a research note on Wednesday, November 20th. D. Boral Capital began coverage on shares of Omeros in a research note on Monday, December 23rd. They issued a “buy” rating and a $36.00 target price for the company. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Omeros in a report on Thursday, December 19th. Three research analysts have rated the stock with a hold rating, two have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $22.50.

Omeros Stock Performance

Shares of OMER stock opened at $11.68 on Friday. Omeros Co. has a fifty-two week low of $2.61 and a fifty-two week high of $13.60. The firm has a market capitalization of $676.86 million, a price-to-earnings ratio of -5.06 and a beta of 1.96. The stock’s 50-day simple moving average is $7.73 and its 200-day simple moving average is $5.41.

Omeros Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.